secwatch.observer — SEC 8-K summary
======================================

Issuer:     Traws Pharma, Inc. (TRAW)
CIK:        0001130598
Form:       8-K
Filed at:   2026-01-26T23:59:59+00:00
Accession:  0001104659-26-006460
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Traws Pharma completes ratutrelvir Phase 2 enrollment; tivoxavir influenza prophylaxis study set for June 2026
--------------------------------------------------------------------------------

- Ratutrelvir study fully enrolled (90 pts); shows fewer AEs, no viral rebound, faster symptom resolution vs PAXLOVID.
- Separate arm for PAXLOVID-ineligible patients addresses high-risk group with few effective options.
- Tivoxavir marboxil compressed tablet predicted to offer 28-day influenza protection; challenge study secured for June 2026 at hVIVO.
- Ratutrelvir's profile may support future studies in reducing risk of Long COVID via early viral clearance.
- CEO states advancement of antiviral portfolio provides significant value inflection points.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1130598/000110465926006460/0001104659-26-006460-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1130598/000110465926006460/tm264027d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-006460

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer